Bioequivalence Testing: The Stats Behind Generic Drug Approvals (Ep. 57)
From Clinical Pharmacology Podcast with Nathan Teuscher · · 24 min
This plays from the publisher's own server. We do not host a copy.
Description
In this episode I discuss bioequivalence testing and how it was developed to support generic drug approvals, but is now a mainstream tool for all of drug development. I discuss the basics of what bioequivalence means, how the studies are designed, and then how to perform the statistical analysis. I end with some examples of how this can be used for both generic drug and innovator drugs to support labeling.
Links discussed in the show:
- FDA Draft Guidance: Statistical Approaches to Establishing Bioequivalence (Dec 2022) (https://www.fda.gov/media/163638/download) – Excellent detail on methods, models, and SAS examples.
- FDA Guidance: Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA. (https://www.fda.gov/media/87219/download)
- Article: “Bioequivalence of generic drugs: a simple explanation for clinicians” (Andrade, 2015) (https://pubmed.ncbi.nlm.nih.gov/26132680/) – Great for the 80-125% intuition.
- R-script with example BE analysis (https://teuschersolutions.com/wp-content/uploads/2026/05/BE-example_r.txt) (Be sure to copy this text into a file and name it "BE-example.R" then you can run it on your local R instance.
- You can connect with Nathan on LinkedIn (https://go.teuschersolutions.com/linkedin) and send me a message
- Send Nathan a message (https://go.teuschersolutions.com/contact)
- Sign up for Nathan’s newsletter (https://go.teuschersolutions.com/newsletter)
Copyright Teuscher Solutions LLC
All Rights Reserved
Back to Clinical Pharmacology Podcast with Nathan Teuscher · Report a problem